Compare Citius Pharmaceuticals Inc (CTXR) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Docusign Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Docusign Inc trades at $59.04 (market cap $11.39B). The key difference: Docusign Inc is far larger — about 608.1× Citius Pharmaceuticals Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | DOCU | |
|---|---|---|
Market Cap | $18.73M | $11.39B |
Sector | Health | Technology |
52-Week High | $1.82 | $85.01 |
52-Week Low | $0.48 | $41.75 |
Enterprise Value | $14.95M | $10.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
DOCU trades at $60.26, up 5.91% today, reflecting strong momentum after consecutive earnings beats. The stock shows bullish technical signals with support at $58 and resistance at $61. Revenue grew to $2.98B in 2025, with net income surging to $1.07B, though cash flow turned negative. Analyst consensus is mixed with a $55.40 price target below the current price, indicating caution despite recent strength.
Outlook balances robust profitability and growth against high valuation and cash flow concerns. The stock offers upside if earnings momentum continues but faces risks from competitive pressures and reliance on subscription renewals. Institutional activity shows mixed signals with some funds reducing stakes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
